Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torax's GERD device backed by FDA advisory panel

This article was originally published in Clinica

Executive Summary

Torax Medical's lead product, the LINX reflux management system, looks set to reach the US market after an FDA advisory panel voted in favour of its approval. Specifically, the panel recommended its use in patients with gastroesophageal reflux disease (GERD) who do not respond to medication, which includes the blockbuster proton pump inhibitor (PPI) drugs such as omeprazole, marketed by AstraZeneca as Losec and Prilosec.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel